Effects of Nf2 missense mutations on schwannomin interactions

Biochemical and Biophysical Research Communications

Volumn 290, Issue 1, 2002, Pages 366-374

  Scoles, Daniel R ^a   Chen, Mercy ^a   Pulst, Stefan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hrs; Merlin; Missense; Mutation; Neurofibromatosis; NF2; p110; Schwannomin; II spectrin

Indexed keywords

ISOPROTEIN; MERLIN; PROTEIN; PROTEIN P110; SPECTRIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN TUMOR; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIMERIZATION; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; TWO HYBRID SYSTEM; YEAST;

FALCO COLUMBARIUS;

EID: 0036295832     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2001.6178     Document Type: Article

References (33)

1. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas
2. Type of mutation in the neurofibromatosis 2 gene (NF2) frequently determines severity of disease
3. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas
4. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas
5. Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas
6. The neuroimaging and clinical spectrum of neurofibromatosis 2
7. Alteration in a new gene coding a putative membrane-organizing protein causes neuro-fibromatosis type 2
8. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppresser
9. Exon scanning for mutation of the NF2 gene in schwannomas
10. Alternative transcripts in the mouse neurofibromatosis type 2 (NF2) gene are conserved and code for schwannomins with distinct C-terminal domains
11. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain
12. Ezrin self-association involves binding of an N-terminal domain to a normally masked C-terminal domain that includes the F-actin binding site
13. Identification of EBP50: A PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family
14. Soluble ezrin purified from placenta exists as stable monomers and elongated dimers with masked C-terminal ezrin-radixin-moesin association domains
15. Merlin differentially associates with the microtubule and actin cytoskeleton
16. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin
17. The neurofibromatosis 2 (NF2) tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate, HRS
18. The neurofibromatosis 2 tumor suppressor schwannomin interacts with βII-spectrin (fodrin)
19. Use of yeast two-hybrid system to evaluate ras interactions with neurofibromin GTPase-activating proteins
20. A novel genetic system to detect protein-protein interactions
21. Structure-function relationships in the ezrin family and the effect of tumor-associated point mutations in neurofibromatosis 2 protein
22. Ezrin: A protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures
23. Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations
24. Interdomain binding mediates tumor growth suppression by the NF2 gene product
25. Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas
26. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas
27. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma
28. Screening for germ-line mutations in the NF2 gene
29. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types
30. A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals
31. Eleven novel mutations in the NF2 tumour suppressor gene
32. A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis 2
33. Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin